---
layout: default
title: Fosfomycin
description: "Fosfomycin çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 75
evidence_level: L3
indication_count: 10
---

# Fosfomycin

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Fosfomycin (å¼—æ–¯é»´ç´ ) - è—¥å¸«è©•ä¼°å ±å‘Š

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Fosfomycin å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
å¼—æ–¯é»´ç´ æ˜¯ä¸€ç¨®å»£è­œæŠ—ç”Ÿç´ ï¼ŒTxGNN é æ¸¬å…¶å°æ·‹ç—…æ€§å°¿é“ç‚æœ‰å¼·æ•ˆï¼ˆæœ‰ RCT æ”¯æŒï¼‰ï¼Œå°å¤šç¨®æ³Œå°¿ç”Ÿæ®–é“æ„ŸæŸ“çš„é æ¸¬èˆ‡å…¶è‡¨åºŠæ‡‰ç”¨é«˜åº¦ä¸€è‡´ï¼Œå±•ç¾äº†çœŸæ­£çš„è€è—¥æ–°ç”¨æ½›åŠ›ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©å­¸å | Fosfomycin |
| å°ç£å•†å“å | ç¦æ–¯é»´ç´ æ³¨å°„åŠ‘ã€å„ªç¦ä¹¾ç²‰æ³¨å°„åŠ‘ã€å„ªå¼—æ–¯é»´ç´ ç­‰ |
| DrugBank ID | DB00828 |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | è¤‡é›œæ€§æ³Œå°¿é“æ„ŸæŸ“ã€æ•—è¡€ç—‡ã€è‚ºç‚ã€è…ç›‚è…ç‚ã€è†€èƒ±ç‚ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | urinary tract infection (disease)ã€gonococcal urethritisã€Ureaplasma urethritisã€uterine inflammatory diseaseã€xanthogranulomatous pyelonephritisã€epiglottitisã€urogenital tuberculosisã€laryngitisã€polyclonal hyperviscosity syndromeã€hyperamylasemia |
| æœ€é«˜è­‰æ“šç­‰ç´š | L2 (æœ‰ RCT ç ”ç©¶) |
| å°ç£ä¸Šå¸‚ç‹€æ…‹ | å¤šé …æœ‰æ•ˆè¨±å¯è­‰ |



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. gonococcal urethritis</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.99%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>å¼—æ–¯é»´ç´ é€éæŠ‘åˆ¶ç´°èŒç´°èƒå£åˆæˆçš„æ—©æœŸæ­¥é©Ÿç™¼æ®æ®ºèŒä½œç”¨ï¼Œå…·æœ‰ç¨ç‰¹çš„ä½œç”¨æ©Ÿè½‰ï¼š</p>

<ol>
<li><strong>æ·‹ç—…æ€§å°¿é“ç‚</strong> (TxGNN Score: 0.9999, Rank: 601)ï¼šå¼—æ–¯é»´ç´ å°æ·‹ç—…å¥ˆç‘ŸèŒæœ‰è‰¯å¥½çš„é«”å¤–æ´»æ€§ï¼Œä¸”åœ¨å¤šé‡æŠ—è—¥æ€§æ™‚ä»£å¯ä½œç‚ºæ›¿ä»£æ²»ç™‚é¸é …ã€‚</li>

<li><strong>å°¿æ¼¿èŒæ€§å°¿é“ç‚</strong> (TxGNN Score: 0.9999, Rank: 603)ï¼šé›–ç„¶å°¿æ¼¿èŒç‚ºéå…¸å‹ç—…åŸèŒï¼Œä½†å¼—æ–¯é»´ç´ çš„å»£è­œç‰¹æ€§å¯èƒ½æä¾›éƒ¨åˆ†è¦†è“‹ã€‚</li>

<li><strong>å­å®®ç‚æ€§ç–¾ç—…</strong> (TxGNN Score: 0.9998, Rank: 775)ï¼šèˆ‡æ³Œå°¿ç”Ÿæ®–é“æ„ŸæŸ“ç›¸é—œï¼Œå¼—æ–¯é»´ç´ çš„çµ„ç¹”ç©¿é€æ€§æ”¯æŒæ­¤é æ¸¬ã€‚</li>

<li><strong>é»ƒè‰²è‚‰èŠ½è…«æ€§è…ç›‚è…ç‚</strong> (TxGNN Score: 0.9998, Rank: 797)ï¼šæ­¤ç‚ºè…ç›‚è…ç‚çš„è®Šç•°å‹ï¼Œèˆ‡åŸæ ¸å‡†çš„è…ç›‚è…ç‚é©æ‡‰ç—‡ç›¸è¿‘ã€‚</li>
</ol>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>### æ·‹ç—…æ€§å°¿é“ç‚è©¦é©—</p>

<p><strong>é—œéµ RCT ç ”ç©¶ï¼ˆNCT ç„¡ç·¨è™Ÿï¼Œæ–‡ç»è¨˜è¼‰ï¼‰ï¼š</strong></p>
<ul>
<li>Yuan Z et al. (2016) åœ¨ä¸­åœ‹éƒ½æ±Ÿå °é†«å­¸ä¸­å¿ƒé€²è¡Œçš„ RCT</li>
<li>æ¯”è¼ƒ fosfomycin trometamol 3gï¼ˆç¬¬ 1ã€3ã€5 å¤©å£æœï¼‰vs ceftriaxone 250mg IM + azithromycin 1g</li>
<li>121 åå®Œæˆè©¦é©—çš„æ‚£è€…åœ¨ç¬¬ 7 å¤©éš¨è¨ªæ™‚å…¨éƒ¨é”åˆ°è‡¨åºŠç—‡ç‹€å’Œé«”å¾µçš„å®Œå…¨ç·©è§£</li>
<li><strong>çµè«–ï¼š</strong> Fosfomycin æ²»ç™‚éè¤‡é›œæ€§æ·‹ç—…æ€§å°¿é“ç‚ç™‚æ•ˆèˆ‡æ¨™æº–æ–¹æ¡ˆç›¸ç•¶</li>
</ul>

<h3>ç›¸é—œæ–‡ç»</h3>

<p>### æ·‹ç—…æ€§å°¿é“ç‚ï¼ˆ6 ç¯‡æ–‡ç»ï¼‰</p>

<ol>
<li><strong>Yuan Z et al. (2016)</strong> - Clinical Microbiology and Infection</li>
</ol>
<ul>
<li><strong>RCT ç ”ç©¶</strong>ï¼šFosfomycin trometamol æ²»ç™‚éè¤‡é›œæ€§æ·‹ç—…æ€§å°¿é“ç‚</li>
<li>ç™‚æ•ˆèˆ‡ ceftriaxone + azithromycin æ¨™æº–æ–¹æ¡ˆç›¸ç•¶</li>
<li>å¾®ç”Ÿç‰©å­¸æ²»ç™’ç‡é” 96.7%</li>

</ul>
<ol>
<li><strong>Lopez-Garcia J (1977)</strong> - Chemotherapy</li>
</ol>
<ul>
<li>æ—©æœŸè‡¨åºŠè©¦é©—ï¼š70 åæ‚£è€…æ¥å— IM fosfomycin æ²»ç™‚</li>
<li>æ€¥æ€§æ·‹ç—…æ€§å°¿é“ç‚ï¼šå–®åŠ‘ 4g æ²»ç™’ç‡ 86%</li>
<li>äºæ€¥æ€§æ·‹ç—…æ€§å°¿é“ç‚ï¼š2g q8h x 2 å¤©é” 100% æ²»ç™’ç‡</li>

</ul>
<ol>
<li><strong>Rodriguez A et al. (1977)</strong> - Chemotherapy</li>
</ol>
<ul>
<li>è¥¿ç­ç‰™å¤šä¸­å¿ƒè©•ä¼°ï¼š959 åæ‚£è€…</li>
<li>æ·‹ç—…å¥ˆç‘ŸèŒæ„ŸæŸ“æ²»ç™’ç‡ 90%</li>
</ul>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. Ureaplasma urethritis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. uterine inflammatory disease</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ2 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01431326" target="_blank">NCT01431326</a></td><td>N/A</td><td>COMPLETED</td><td>3520</td><td>Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04278404" target="_blank">NCT04278404</a></td><td>N/A</td><td>RECRUITING</td><td>5000</td><td>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ1 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35653789/" target="_blank">35653789</a></td><td>2022</td><td>Article</td><td>Journal of obstetric</td><td>The dienogest-related cystitis in women with endometriosis: ...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. xanthogranulomatous pyelonephritis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. epiglottitis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.93%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. urogenital tuberculosis</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.88%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ2 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26390556/" target="_blank">26390556</a></td><td>2015</td><td>Article</td><td>Urologiia (Moscow, R</td><td>[REASONS OF DELAYED DIAGNOSIS OF BLADDER TUBERCULOSIS].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28248018/" target="_blank">28248018</a></td><td>2016</td><td>Article</td><td>Urologiia (Moscow, R</td><td>[Diagnosis and treatment of cystitis: more questions than an...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. laryngitis</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.68%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ4 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11489366/" target="_blank">11489366</a></td><td>2001</td><td>Article</td><td>Auris, nasus, larynx</td><td>Fosfomycin nebulizer therapy to chronic sinusitis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/1796687/" target="_blank">1796687</a></td><td>1991</td><td>Article</td><td>Zentralblatt fur Vet</td><td>Selective medium containing fosfomycin, nalidixic acid, and ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6529372/" target="_blank">6529372</a></td><td>1984</td><td>Article</td><td>Auris, nasus, larynx</td><td>Mechanism of protective effect of fosfomycin against aminogl...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/740310/" target="_blank">740310</a></td><td>1978</td><td>Article</td><td>Minerva medica</td><td>[Use of fosfomycin in pediatrics with particular reference t...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. polyclonal hyperviscosity syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.47%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. hyperamylasemia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.47%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. pyelitis</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.37%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36031053/" target="_blank">36031053</a></td><td>2023</td><td>Article</td><td>Clinical microbiolog</td><td>Urinary tract infections in pregnancy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31608743/" target="_blank">31608743</a></td><td>2020</td><td>Article</td><td>Postgraduate medicin</td><td>Treatment of urinary tract infections in the era of antimicr...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30861061/" target="_blank">30861061</a></td><td>2019</td><td>Article</td><td>Clinical infectious </td><td>Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazoba...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33819054/" target="_blank">33819054</a></td><td>2021</td><td>Article</td><td>Annals of internal m</td><td>Appropriate Use of Short-Course Antibiotics in Common Infect...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23958364/" target="_blank">23958364</a></td><td>2013</td><td>Article</td><td>Primary care</td><td>Urinary tract infections.</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

**æœ‰æ•ˆè¨±å¯è­‰ï¼š**

| è¨±å¯è­‰å­—è™Ÿ | å•†å“å | è¨±å¯è­‰æŒæœ‰è€… | æ•ˆæœŸ |
|------------|--------|--------------|------|
| è¡›ç½²è—¥è£½å­—ç¬¬029724è™Ÿ | ç¦æ–¯é»´ç´ æ³¨å°„åŠ‘ | æ„æ¬£åœ‹éš› | 2028/05/28 |
| è¡›ç½²è—¥è£½å­—ç¬¬038962è™Ÿ | å„ªå¼—æ–¯é»´ç´ éœè„ˆæ³¨å°„åŠ‘ | å„ªè‰¯åŒ–å­¸ | 2030/06/20 |
| è¡›ç½²è—¥è£½å­—ç¬¬035049è™Ÿ | å„ªç¦ä¹¾ç²‰æ³¨å°„åŠ‘ | é”å¯Œåº·åœ‹éš› | 2027/03/27 |
| è¡›ç½²è—¥è¼¸å­—ç¬¬020462è™Ÿ | å¼—å¸ç¦é»´ç´  | å‰æ·³ä¼æ¥­ | 2029/05/24 |
| è¡›éƒ¨è—¥é™¸è¼¸å­—ç¬¬001032è™Ÿ | è†¦çµ²èŒç´ å”ä¸ä¸‰é†‡èƒºé¹½ | æ’äºè²¿æ˜“ | 2026/11/26 |

**æ ¸å‡†é©æ‡‰ç—‡ï¼š**
- è¤‡é›œæ€§æ³Œå°¿é“æ„ŸæŸ“
- æ„ŸæŸ“æ€§å¿ƒå…§è†œç‚
- éª¨åŠé—œç¯€æ„ŸæŸ“
- é™¢å…§å‹è‚ºç‚ï¼ˆå«å‘¼å¸å™¨ç›¸é—œè‚ºç‚ï¼‰
- ç´°èŒæ€§è…¦è†œç‚
- è¤‡é›œæ€§è…¹è…”å…§æ„ŸæŸ“

## å®‰å…¨æ€§è€ƒé‡

### å¸¸è¦‹ä¸è‰¯åæ‡‰
- è…¸èƒƒé“ç—‡ç‹€ï¼ˆè…¹ç€‰ã€å™å¿ƒï¼‰
- é ­ç—›
- é™°é“ç‚

### è—¥ç‰©äº¤äº’ä½œç”¨

| äº¤äº’ä½œç”¨è—¥ç‰© | åš´é‡ç¨‹åº¦ | èªªæ˜ |
|--------------|----------|------|
| Metoclopramide | Moderate | å¯èƒ½é™ä½ fosfomycin è¡€ä¸­æ¿ƒåº¦ |
| åˆ¶é…¸åŠ‘ | Minor | å¯èƒ½å½±éŸ¿å¸æ”¶ |

### ç‰¹æ®Šæ—ç¾¤
- **è…åŠŸèƒ½ä¸å…¨**ï¼šéœ€æ ¹æ“š CrCl èª¿æ•´åŠ‘é‡
- **å­•å©¦**ï¼šå£æœåŠ‘å‹ç‚º FDA æ‡·å­•åˆ†é¡ B ç´š
- **å…’ç«¥**ï¼šå£æœåŠ‘å‹é©ç”¨æ–¼ 12 æ­²ä»¥ä¸Š

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

**ä¹³è£½å“ï¼ˆç‰›å¥¶ã€å„ªæ ¼ã€èµ·å¸ï¼‰** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šé«˜éˆ£é£Ÿç‰©å¯èƒ½é™ä½ Fosfomycin å¸æ”¶
- å»ºè­°ï¼šç©ºè…¹æœç”¨æ•ˆæœæœ€ä½³


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**è…è‡Ÿç–¾ç—…** ğŸ”´ Major
- æ³¨æ„äº‹é …ï¼šFosfomycin is eliminated unchanged by the kidney (38%) and in the feces (18%)...

**Diseases requiring hemodialysis** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šFosfomycin is removed by hemodialysis and should be administered after dialysis sessions...

**Colitis** ğŸŸ¢ Minor
- é¢¨éšªåŒ…æ‹¬ï¼šæ„ŸæŸ“ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### é æ¸¬è©•ä¼°çµè«–

Fosfomycin çš„é æ¸¬é©æ‡‰ç—‡ä¸­ï¼Œ**æ·‹ç—…æ€§å°¿é“ç‚æ˜¯æœ€å…·è‡¨åºŠè½‰è­¯åƒ¹å€¼çš„ç™¼ç¾**ã€‚åœ¨æ·‹ç—…å¥ˆç‘ŸèŒå¤šé‡æŠ—è—¥æ€§æ—¥ç›Šåš´é‡çš„ä»Šæ—¥ï¼Œfosfomycin å¯èƒ½æˆç‚ºé‡è¦çš„æ›¿ä»£æ²»ç™‚é¸é …ã€‚

### è­‰æ“šç­‰ç´šç¸½çµ

| é æ¸¬é©æ‡‰ç—‡ | TxGNN Score | è­‰æ“šç­‰ç´š | è©•ä¼° |
|------------|-------------|----------|------|
| æ·‹ç—…æ€§å°¿é“ç‚ | 0.9999 | **L2** | æœ‰ RCT æ”¯æŒï¼Œé«˜åº¦æ¨è–¦ |
| å­å®®ç‚æ€§ç–¾ç—… | 0.9998 | L3 | æœ‰è§€å¯Ÿæ€§ç ”ç©¶æ”¯æŒ |
| è…ç›‚è…ç‚ï¼ˆè®Šç•°å‹ï¼‰ | 0.9998 | L2 | èˆ‡ç¾æœ‰é©æ‡‰ç—‡ç›¸è¿‘ |
| å–‰é ­ç‚ | 0.997 | L4 | æœ‰å‰è‡¨åºŠ/ç—…ä¾‹å ±å‘Š |

### å»ºè­°

1. **æ·‹ç—…æ€§å°¿é“ç‚**ï¼š
   - **å¼·çƒˆå»ºè­°é€²ä¸€æ­¥è©•ä¼°**
   - ç¾æœ‰ RCT æ•¸æ“šæ”¯æŒç™‚æ•ˆ
   - é©åˆå¤šé‡æŠ—è—¥æ€§ç’°å¢ƒä¸‹ä½œç‚ºæ›¿ä»£æ–¹æ¡ˆ
   - å»ºè­°å‘ TFDA ç”³è«‹é©æ‡‰ç—‡æ“´å¢

2. **å…¶ä»–æ³Œå°¿ç”Ÿæ®–é“æ„ŸæŸ“**ï¼š
   - èˆ‡ç¾æœ‰é©æ‡‰ç—‡ç¯„åœç›¸è¿‘
   - è‡¨åºŠä¸Šå·²æœ‰ä½¿ç”¨ç¶“é©—

3. **æŠ—è—¥æ€§è€ƒé‡**ï¼š
   - Fosfomycin ç¨ç‰¹çš„ä½œç”¨æ©Ÿè½‰ä½¿å…¶æˆç‚ºå°æŠ— ESBL å’Œ CRE çš„é‡è¦é¸é …
   - æ‡‰å¯©æ…ä½¿ç”¨ä»¥å»¶ç·©æŠ—è—¥æ€§ç™¼å±•

---

*å ±å‘Šç”Ÿæˆæ—¥æœŸï¼š2026-02-11*
*è³‡æ–™ä¾†æºï¼šTxGNN çŸ¥è­˜åœ–è­œé æ¸¬ã€ClinicalTrials.govã€PubMedã€å°ç£ FDA*

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Fenoprofen]({{ "/drugs/fenoprofen/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Fenoterol]({{ "/drugs/fenoterol/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Travoprost]({{ "/drugs/travoprost/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Brivaracetam]({{ "/drugs/brivaracetam/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Zanubrutinib]({{ "/drugs/zanubrutinib/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Fosfomycinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/fosfomycin/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_fosfomycin,
  title = {Fosfomycinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/fosfomycin/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
